Impact of antipsychotics on cytokine production in-vitro

Journal of Psychiatric Research

Volumn 45, Issue 10, 2011, Pages 1358-1365

  Himmerich, Hubertus ^a   Schönherr, Jeremias ^a   Fulda, Stephany ^b   Sheldrick, Abigail J ^c   Bauer, Katrin ^a   Sack, Ulrich ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Chlorpromazine; Clozapine; Cytokines; Haloperidol; IL 17; Quetiapine; TSST 1

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NEUROLEPTIC AGENT; NORCLOZAPINE; QUETIAPINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CELL; CELL SECRETION; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE SYSTEM; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

EID: 80053120341     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.04.009     Document Type: Article

References (55)

1. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry 2000, 5:150-158.
2. Barak V., Barak Y., Levine J., Nisman B., Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic and Clinical Physiology and Pharmacology 1995, 6:61-69.
3. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265.
4. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biological Psychiatry 1995, 38:297-302.
5. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. The American Journal of Psychiatry 2010, 167:261-280.
6. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., Clerici M., et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1998, 22:947-957.
7. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002, 26:33-39.
8. Chedid L. Comparative action of promethazine, chlorpromazine and cortisone in mice receiving fatal doses of a bacterial endotoxin. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 1954, 148:1039-1043.
9. Dinges M.M., Orwin P.M., Schlievert P.M. Exotoxins of Staphylococcus aureus. Clinical Microbiology Reviews 2000, 13:16-34.
10. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. International Journal of Neuropsychopharmacology 2011, [Epub].
11. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behaviour and Immunity 2006, 20:532-545.
12. Egwuagu C.E. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 2009, 47:149-156.
13. Geiger H., Finkelstein B.A. Largactil in the treatment of tuberculosis. Schweizerische Medizinische Wochenschrift 1954, 84:1063-1064.
14. Hammarström S., Hammarström M.L., Sundblad G., Arnarp J., Lönngren J. Mitogenic leukoagglutinin from Phaseolus vulgaris binds to a pentasaccharide unit in N-acetyllactosamine-type glycoprotein glycans. Proceedings of the National Academy of Sciences of the United States of America 1982, 79:611-615.
15. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmunity Reviews 2010, 9:785-792.
16. Hess E.V. Drug-related lupus. Current Opinion in Rheumatology 1991, 3:809-814.
17. Himmerich H., Kaufmann C., Schuld A., Pollmächer T. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. Journal of Psychiatric Research 2005, 39:35-42.
18. Himmerich H., Fulda S., Sheldrick A.J., Blümäkers B., Rink L. Interferon-γ reduction by tricyclic antidepressants. International Journal of Psychiatry in Medicine 2010, 40:413-424.
19. Himmerich H., Kirkby K.C., Steinberg H. From Julius Wagner-Jauregg to biomarkers and immunological therapies. The World Journal of Biologic Psychiatry 2010, 11:154-155.
20. Himmerich H., Milenović S., Fulda S., Plümäkers B., Sheldrick A.J., Michel T.M., et al. Regulatory T cells increased while IL-1β decreased during antidepressant therapy. Journal of Psychiatric Research 2010, 44:1052-1057.
21. Himmerich H., Sorge S., Kirkby K.C., Steinberg H. Schizophrenic disorders: the development of immunological concepts and therapy in psychiatry. Nervenarzt 2011, [Epub].
22. Hinze-Selch D., Pollmächer T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain, Behavior and Immunity 2001, 15:282-318.
23. Hinze-Selch D., Mullington J., Pollmächer T. Clozapine, cytokines, fever and sleep. Wiener Medizinische Wochenschrift 1996, 146:311-313.
24. International Schizophrenia Consortium, Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
25. Ising M., Lauer C.J., Holsboer F., Modell S. The Munich vulnerability study on affective disorders: premorbid neuroendocrine profile of affected high-risk probands. Journal of Psychiatric Research 2005, 39:21-28.
26. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 Stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. Journal of Immunology 1998, 160:3513-3521.
27. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
28. Kirchner H., Kleinicke C., Digel W. A whole-blood technique for testing production of human interferon by leukocytes. Journal of Immunological Methods 1982, 48:213-219.
29. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
30. Leykin I., Mayer R., Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997, 37:75-86.
31. Li Y., Xiao B., Qiu W., Yang L., Hu B., Tian X., et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. Journal of Affective Disorders 2010, 124:68-75.
32. Liberman A.C., Druker J., Refojo D., Holsboer F., Arzt E. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB Journal 2009, 23:1558-1571.
33. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. The American Journal of Psychiatry 1993, 150:1408-1410.
34. Liu L., Jia F., Yuan G., Chen Z., Yao J., Li H., et al. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Research 2010, 176:1-7.
35. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. The American Journal of Psychiatry 1995, 152:1291-1297.
36. Müller N., Schwarz M.J. Immune system and schizophrenia. Current Immunology Reviews 2010, 6:213-220.
37. Murdaca G., Colombo B.M., Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Internal and Emergency Medicine 2011, [Epub].
38. Na K.S., Kim Y.K. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007, 56:55-63.
39. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Research 2008, 160:256-262.
40. O'Donnell M.C., Catts S.V., Ward P.B., Liebert B., Lloyd A., Wakefield D., et al. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Research 1996, 65:171-178.
41. Papiol S., Rosa A., Gutiérrez B., Martín B., Salgado P., Catalán R., et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. Journal of Medical Genetics 2004, 41:219-223.
42. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology 2005, 6:1133-1141.
43. Parker C.W. Biochemical changes taking place in mitogen-treated lymphocytes. Methods in Enzymology 1987, 150:29-83.
44. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. Journal of Clinical Psychopharmacology 1996, 16:403-409.
45. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
46. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clinical Immunology and Immunopathology 1996, 78:83-85.
47. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
48. Singh R.K., Shi J., Zemaitaitis B.W., Muma N.A. Olanzapine increases RGS7 p.otein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. Journal of Pharmacology and Experimental Therapeutics 2007, 322:133-140.
49. Söderlund J., Schröder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., et al. Activation of brain interleukin-1beta in schizophrenia. Molecular Psychiatry 2009, 14:1069-1071.
50. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
51. Sullivan P.F. The psychiatric GWAS consortium: big science comes to psychiatry. Neuron 2010, 68:182-186.
52. Tarazona R., González-García A., Zamzami N., Marchetti P., Frechin N., Gonzalo J.A., et al. Chlorpromazine amplifies macrophage-dependent IL-10 p.oduction in vivo. Journal of Immunology 1995, 154:861-870.
53. Wagner-Jauregg J. Ueber die Einwirkung fieberhafter Erkrankungen auf Psychosen. Jahrbuch für Psychiatrie 1887, 7:94-131.
54. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 1996, 246:279-284.
55. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophrenia Research 2002, 57:247-258.